Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) FCF Margin (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed FCF Margin for 6 consecutive years, with 221.9% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin fell 28407.0% to 221.9% in Q3 2025 year-over-year; TTM through Sep 2025 was 873.6%, a 104648.0% increase, with the full-year FY2024 number at 5455.16%, down 514285.0% from a year prior.
  • FCF Margin was 221.9% for Q3 2025 at Marker Therapeutics, down from 218.11% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1905.43% in Q3 2023 to a low of 1575.39% in Q1 2025.
  • A 4-year average of 257.72% and a median of 218.11% in 2025 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: skyrocketed 235114bps in 2023, then plummeted -184326bps in 2024.
  • Marker Therapeutics' FCF Margin stood at 1256.37% in 2022, then soared by 174bps to 935.05% in 2023, then crashed by -88bps to 113.62% in 2024, then tumbled by -295bps to 221.9% in 2025.
  • Per Business Quant, the three most recent readings for MRKR's FCF Margin are 221.9% (Q3 2025), 218.11% (Q2 2025), and 1575.39% (Q1 2025).